乳腺癌治疗中周期蛋白依赖性激酶4/6抑制剂耐药机制研究进展  

A review of molecular mechanisms of drug resistance to cyclin-dependent kinases 4/6 inhibitors in breast cancer

作　　者：李睿[1] 王斌[1] 贾红燕[1] Li Rui;Wang Bin;Jia Hongyan(Department of Glandbreast Surgery,the First Hospital of Shanxi Medical University,Taiyuan 030012,China)

机构地区：[1]山西医科大学第一医院乳腺外科,太原030012

出　　处：《中华实验外科杂志》2021年第4期784-789,共6页Chinese Journal of Experimental Surgery

基　　金：山西省留学人员科技活动择优资助项目(20200036)。

摘　　要：乳腺癌的发病率和死亡率居全球女性恶性肿瘤之首。目前新的靶向药物在乳腺癌治疗中取得较大进展。作为抗肿瘤靶点之一的周期蛋白依赖性激酶4/6(CDK4/6)抑制剂对乳腺癌的治疗表现出很好的临床活性,但耐药性问题限制药物疗效。我们就目前影响CDK4/6抑制剂疗效及耐药的分子机制进展作一综述,探究克服其耐药性产生的办法,为后续的机制研究提供基础。Breast cancer is a common malignant tumor in women,and both incidence and mortality are the top among all the female malignant tumors.At present,new target therapy made great progress in the treatment of breast cancer.As one of the anti-tumor targets drug,cyclin-dependent kinases 4/6(CDK4/6)inhibitor shows good clinical activity in the treatment of breast cancer.Despite promising clinical outcomes,drug resistance to CDK4/6 inhibitors has limited the success of these treatments.So we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors,to explore the way of overcoming these resistance,and provide ideas for future research.

关 键 词：乳腺癌 耐药 机制 

分 类 号：R737.9[医药卫生—肿瘤]